Status:
RECRUITING
Imjudo & Imfinzi PMS
Lead Sponsor:
AstraZeneca
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
Brief Summary
Based on the re-review of new drugs article, Korean pharmaceutical act, the objectives of this study are to assess safety and effectiveness of the study drugs(Imjudo \& Imfinzi) in a real world settin...
Detailed Description
Primary Objective: To assess safety of the study drugs for patients treated with the study drugs under the approved indication in Korea Secondary Objective: To assess effectiveness of the study dru...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients eligible for the study drugs according to the approved label in Korea
- Provision of signed and dated written informed consent by the patient or legally acceptable representative
- Exclusion criteria:
- Other off-label indications according to the approved label in South Korea
- Current participation in any interventional trial
Exclusion
Key Trial Info
Start Date :
April 14 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 28 2029
Estimated Enrollment :
246 Patients enrolled
Trial Details
Trial ID
NCT06544629
Start Date
April 14 2025
End Date
February 28 2029
Last Update
November 21 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Busan, South Korea
2
Research Site
Goyang, South Korea
3
Research Site
Seongnam, South Korea
4
Research Site
Seoul, South Korea